02157 LEPU BIO-B
- 3.050
- -0.150-4.69%
LEPU BIO-B News
Hong Kong stock market anomaly | Some pharmaceutical stocks rise, medical insurance negotiations support innovative drugs. Institutions point out that the sector still has further room for recovery.
Some pharmaceutical stocks rose, as of the deadline, SciClone Pharmaceuticals-B (02171) rose by 33.68% to HK$8.97; Concord Jingrui Pharmaceuticals-B (09966) rose by 10.34% to HK$4.27; LuPu Biotech-B (02157) rose by 7.87% to HK$3.29.
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt
Lepu Biopharma Cancer Drug's NDA Approved by China's NDMA; Stocks Up 8%
Luoping Biosciences-B (02157.HK): MRG003 for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) has been accepted for new drug application by the National Medical Products Administration and included in priority review.
September 27, Geelonghui - The company LePu Biology-B (02157.HK) announced that it has received the "Acceptance Notice" issued by the China National Medical Products Administration (NMPA). The company's candidate drug MRG003 (an epidermal growth factor receptor (EGFR) targeted antibody-drug conjugate (ADC) candidate drug for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC))'s new drug application (NDA) has been accepted. MRG003 has also been included in the priority review by the NMPA Center for Drug Evaluation (CDE) ("Priority Review").
Luopu Biology-B (02157): NMPA accepted the drug registration application of MRG003 and included it in the priority review.
Lupe Bio-B (02157) announced that the company has received the issuance from the National Medical Products Administration (NMPA) of china...
Express News | Lepu Biopharma Co Ltd - Acceptance of New Drug Application and Priority- Review Granted by Nmpa to- Mrg003
LEPU BIO-B: 2024 Interim Report
Hong Kong stock abnormal | Livzon Pharmaceutical Group Inc. - B (02157) is now up more than 4%, the injection of Vedolizumab is planned to be included in priority review.
Lepu Medical-B(02157) is now up more than 4%. As of the time of writing, it has increased by 4.44%, reaching 3.06 Hong Kong dollars, with a turnover of 8.1931 million Hong Kong dollars.
HKEX market abnormal movement | Livzon Pharmaceutical Group Inc - Class B (02157) fell more than 3% after performance announcement, with a net loss attributable to shareholders of 192 million yuan in the first half of the year, a year-on-year increase of
LePu Biotechnology-B (02157) fell more than 3% after the performance announcement, as of the time of publication, it fell 3.46%, with a price of HK$2.23 and a turnover of HK$5.6623 million.
Luoping Biological-B (02157) released its interim performance, with a shareholder's attributable loss of 0.192 billion yuan, a year-on-year increase of 35.6%.
Le Pu Biological-B (02157) released its six-month performance as of June 30, 2024, with a revenue of 0.133 billion...
Express News | Lepu Biopharma H1 Adjusted Net Income RMB -192.4 Million
Express News | Lepu Biopharma H1 Revenue RMB 94.8 Million
LEPU BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Livzon Pharmaceutical Group Inc. - Class B (02157.HK) plans to hold a board of directors meeting on August 21 to approve its interim performance.
LePu Biotechnology-B(02157.HK) announced on August 9th that the board of directors meeting will be held on Wednesday, August 21, 2024 to consider and approve the unaudited interim performance of the company and its subsidiaries for the six months ending June 30, 2024, including recommending the distribution of interim dividends (if any), and handling other matters.
LEPU BIO-B: NOTICE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Leaping Bio (02157) candidate drug MRG003 has been granted breakthrough designation for the treatment of FDA.
Jingu Wealth News | BeiGene (02157) announced that its candidate drug MRG003 (a monoclonal antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), as well as the company's core product) has recently been granted breakthrough therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/MNPC). It is reported that BTD is designed to promote and accelerate the development and evaluation of new drugs for the treatment of severe diseases that have preliminary evidence of significant clinical advantages compared to existing therapeutic drugs. MRG0
Livzon Pharmaceutical Group Inc. -B (02157.HK): MRG003 has received FDA breakthrough therapy designation for the treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
Le Pu Biological -B (02157.HK) issued an announcement on August 5. The company's candidate drug MRG003 (a epidermal growth factor receptor-targeted antibody-drug conjugate ("ADC") candidate drug and the company's core product) has recently been granted Breakthrough Therapy Designation ("BTD") by the US Food and Drug Administration ("FDA") for the treatment of recurrent or metastatic nasopharyngeal carcinoma ("R/M NPC"). Prior to this, MRG003 had already received BTD from the Drug Evaluation Center ("CDE") of the National Medical Products Administration (China).
Express News | Lepu Biopharma Co - Mrg003 Granted Breakthrough Therapy Designation by US FDA
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
Analysis
Price Target
No Data
No Data